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Venous thromboembolism is a well-established complication of total hip and knee arthroplasty and hip
fracture surgery. Clinical practice guidelines have been proposed to help clinicians provide prophylaxis
against this risk. However, most guidelines reference data that are becoming outdated because of new
advances in perioperative protocols. Recent data would suggest that aspirin may be appropriate for most
patients after total hip and knee replacement and a more potent chemoprophylaxis for higher risk patients. Low-molecular-weight heparin remains the recommended choice after hip fracture surgery,
although there is a paucity of recent literature in this patient population. There are randomized trials
currently underway in the arthroplasty population that may guide clinicians in the appropriate choice of
chemoprophylaxis. These studies should inform updates to the current clinical practice guidelines.
© 2021 Published by Elsevier Inc. on behalf of The American Association of Hip and Knee Surgeons. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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Introduction
Venous thromboembolism (VTE), comprised of deep venous
thrombosis and pulmonary embolism, can be a devastating
complication of orthopedic surgery and may occur due to surgical
trauma and perioperative immobility. We aim to brieﬂy review
current clinical practice guidelines (CPGs) for the prevention of VTE
after hip and knee replacement and hip fracture surgery (HFS) and
highlight evidence that supports an update to these CPGs.
Postoperative VTE may be suspected clinically when patients
present with acute leg pain, swelling, erythema, warmth, hypotension, hemoptysis, chest pain, or dyspnea. Diagnosis may be
supplemented with laboratory tests, but deep venous thrombosis is
typically conﬁrmed with venous ultrasound, and pulmonary embolism with computed tomography angiogram of the pulmonary
arteries. In addition to the morbidity and possible mortality that
can result from VTE, a signiﬁcant ﬁnancial burden is placed on the
health-care system, with an estimated cost of $33,000 US dollars
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per VTE event after 1 year [1]. VTE is of particular concern after total
joint arthroplasty (TJA) and HFS because of the increasing volume
of these procedures, the older age of the patients, and their associated comorbidities. Orthopedic surgeons and hospitalists often
comanage these patients because of evidence of improvements in
care and reduced costs [2]; therefore, knowledge of the safety and
efﬁcacy of chemoprophylaxis after TJA and HFS is necessary for all
teams involved. Fortunately, the incidence of VTE after HFS and TJA
has declined in recent decades with combined pharmacologic and
mechanical prophylaxis, advances in surgical and anesthetic techniques, improvements in perioperative pain control, and early
mobilization [3]. Current rates have been reported as 0.83%-1.5%
after HFS, 0.6%-1.2% after total hip arthroplasty (THA), and 0.3%1.4% after total knee arthroplasty (TKA) [4-6].
Problem statement
Many medical societies have created CPG for VTE prophylaxis in
orthopedic surgery, including after TJA and HFS. Guidelines from
the American Academy of Orthopedic Surgeons, the American
College of Chest Physicians, the National Institute for Health and
Care Excellence from the Department of Health in England, and the
American Society of Hematology are summarized in Table 1. These
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Table 1
Summary of pharmacologic recommendations in CPGs for VTE prevention after TKA, THA, and HFS.
Clinical practice guideline

AAOS (TJA 2011, HFS 2014)
[31,32]

ACCP (2012) [33]

NICE (2021) [34]

ASH (2019) [35]

Recommends pharmacologic
prophylaxis but does not
recommend speciﬁc agents
Duration: Does not specify

LMWH, ASA, fondaparinux,
apixaban, dabigatran,
rivaroxaban, UH, VKA
Duration: minimum 10-14 d

LMWH, ASA, or rivaroxaban
(consider apixaban or
dabigatran if others cannot be
used)
Duration: 14 d

ASA or anticoagulants (AC)
When AC used DOAC preferred
over LMWH which is preferred
over UH.
Duration: Beyond 3 wk (19-42 d)

THA

Recommends pharmacologic
prophylaxis but does not
recommend speciﬁc agents
Duration: Does not specify

Same as TKA

Same as TKA

HFS

Recommends pharmacologic
prophylaxis but does not
recommend speciﬁc agents
Duration: Does not specify

LMWH, ASA, fondaparinux, UH,
VKA
Duration: minimum 10-14 d

LMWH (10 d) followed by ASA
(28 d), LMWH (28 d), or
rivaroxaban (consider apixaban
or dagibatan if others cannot be
used)
LMWH or fondaparinux
Duration: 1 mo

Surgical procedure
TKA

LMWH or UH.
Duration: Beyond 3 wk (19-42 d)

Although not listed, all recommend IPC.
AAOS, American Academy of Orthopedic Surgeons; ACCP, American College of Chest Physicians; ASA, aspirin; ASH, American Society of Hematology; fondaparinux, fondaparinux sodium; IPC, intermittent pneumatic compression device; NICE, National Institute for Health and Care Excellence; UH, unfractionated heparin; VKA, adjusted-dose
vitamin K antagonist.

guidelines all agree that some form of prophylaxis is necessary;
however, there is no consensus on choice of agent or duration. All
suggest more potent prophylaxis in patients who have risk factors
for VTE, especially in patients with prior history of VTE. In addition,
all suggest the use of mechanical prophylaxis with intermittent
pneumatic compression unless contraindicated.
It is important to recognize that some of these guidelines
(American Academy of Orthopedic Surgeons and American College
of Chest Physicians) are nearly 10 years old or older. In addition,
although the National Institute for Health and Care Excellence
guidelines are more recently updated, some recommendations are
over 10 years old, and more importantly, the majority of the literature cited to create the recommendations dates from the 1970s to
early 2000s. Although the American Society of Hematology TJA
guidelines include citations dated in the 2010s, this is not the case
for the HFS guidelines. In fact, all HFS CPGs mentioned almost
exclusively cite literature dated 2000 or earlier. This statement is
not to place fault on the CPG but rather to highlight the paucity of
new research directed in this area. The past 10 years have been
marked by signiﬁcant advances in recovery after TJA and HFS,
including multimodal pain management, regional anesthesia,
blood conservation with medications such as tranexamic acid, and
early ambulation [7]. These older CPG risk and beneﬁt assessments,
therefore, may not be based on the current VTE risk.
Proposed solution
The optimal chemoprophylactic agent would minimize both the
risks of VTE and bleeding, while being cost-effective and easy to
administer. While no single medication has yet to be identiﬁed,
aspirin, for example, has been gaining clinical acceptance for prophylaxis after TJA as its safety and efﬁcacy have been demonstrated
repeatedly [8-13]. A recent systematic review and meta-analysis of
randomized controlled trials found no difference in VTE or adverse
events when comparing aspirin with other anticoagulants after TJA
[14]. Registry studies have shown aspirin to be noninferior to other
forms of anticoagulation after both TKA [15] and THA [16]. However,
controversy surrounding aspirin remains [17,18]. The direct oral
anticoagulants (DOACs) have gained acceptance given their ease of
administration and potential for fewer VTE events. A recent study
using the National Joint Registry for England Wales, Northern Island,
and the Isle of Man compared DOACs to aspirin after THA and TKA

and found that DOACs were associated with a lower risk of VTE and
no higher risk of mortality or complications except for renal injury
[19]. These medications were not approved during the time period
of many of the studies referenced in the preparation of the referenced CPGs. DOACs are more potent anticoagulants, however, and
there are reports of increased wound complications and reoperation
with their use [20,21]. In HFS, 2 recent studies compared DOACs to
low-molecular-weight heparin (LMWH) and found either no difference [22] or reduced [23] VTE rates in the DOAC group, although
these studies included small sample sizes. Another recent study in
HFS compared aspirin to rivaroxaban after 5 days of LMWH and
found no difference in VTE or bleeding events [24].
With the current pharmacologic prophylaxis strategies available,
providers seek to balance low VTE rates while minimizing other
complications related to anticoagulation such as bleeding and wound
complications. In recent years, with patients mobilizing earlier
postoperatively, the balance has shifted toward using less-potent
anticoagulation such as aspirin after TJA in low-risk patients. Interest in identifying patient risk factors to tailor the appropriate VTE
prophylaxis to individual patients has been rising [25,26]. There is
much focus on one agent over another, but the real challenge is
determining the appropriate threshold of risk factors for the use of a
given agent in a particular patient. For TJA, recent data [8-16] support
that aspirin is appropriate for most patients with modern pain
management and mobilization protocols. Low-dose aspirin appears
to be sufﬁcient [27,28]. Still, there is a small group of patients that
should likely receive more aggressive anticoagulation [29], possibly
DOACs, after primary TJA. In HFS, despite the outdated evidence and
given the advances in perioperative management, there are currently
no recent well-designed studies or ongoing trials being conducted to
help provide updated recommendations.
Future direction and long-term focus
Furthermore, high-quality research is necessary to help provide
more detailed guidelines; however, this remains challenging
because of the low event rates, need for large sample sizes, and
costs associated with performing large-scale studies. In TJA, there is
currently one ongoing trial nested within the Australian Orthopaedic Association National Joint Replacement Registry, known as
CRISTAL, which is a cluster randomized, crossover trial comparing
aspirin and LMWH after TKA and THA in over 15,000 patients
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(ACTRN12618001879257). In addition, the Pulmonary Embolism
Prevention after Hip and Knee Replacement trial (PEPPER;
NCT02810704) is a randomized trial comparing aspirin, rivaroxaban, and warfarin in 20,000 patients undergoing THA and TKA in
the United States. Studies such as these will hopefully help elucidate the optimal agent for these patients given their individual risk
factors. We hope to see the development of similar studies for the
hip fracture population as well.
Recommendations
Patients undergoing TJA or HFS are frequently on preoperative
anticoagulation. A comprehensive discussion of preoperative
management is out of the scope of this review but was well detailed
in a recent review by Barlow et al. [30]. The choice of VTE prophylaxis after TJA and HFS is ultimately at the discretion of the
treating physician but should be tailored to the individual patient
and should continue for at least 14 days, with consideration of a 4week duration in high-risk patients. Low-dose aspirin is likely
appropriate after primary, lower extremity TJA for the vast majority
of patients without an increased personal risk of VTE. DOACs are
preferred in higher risk patients. Although no consensus exists to
deﬁne high risk, the treating physician may consider a high-risk
patient to be one with a personal or family history of VTE, active
cancer, hypercoagulable state, or multiple medical comorbidities
such as cardiac disease, pulmonary disease, diabetes mellitus, and
morbid obesity [26]. For HFS, LMWH is recommended for most
patients, but aspirin is supported in some guidelines. As further
high-quality clinical trials are completed, and guidelines are
updated to reﬂect current practice, clinical practice can be modiﬁed
accordingly.
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